PExA develops and commercializes a unique technology aimed for the discovery of early biomarkers in the field of respiratory medicine.
The original idea and research behind the method comes from Professor Anna-Carin Olin’s research group at the Department of Occupational and Environmental Medicine (AMM) at the Sahlgrenska Academy at the University of Gothenburg and is based on a completely new method for collecting material from the small airways: particles in exhaled air. A subsequent analysis of the particles makes it possible to easily identify chemical changes in the composition and to identify potential biomarkers for respiratory diseases.
PExA provides lung researchers with a simple and non-invasive method for collection of microscopic particles, potential biomarkers for diseases in the small airways. The method allows scientists to easily access a sample of the fluid layer covering the small airways. The purpose is to facilitate the development of reliable and more individualised diagnosis, monitoring and treatment of respiratory diseases.
The PExA method can be used to develop diagnostic products in various respiratory diseases, such as COPD, asthma, tuberculosis, cystic fibrosis and lung cancer.
Board & Management
PExA's board and management include individuals with extensive experience and knowledge. Their task is to identify our targets and our strategy.Read More ››
Business Concept and Vision
PExA’s business concept is to give lung researchers a new, unique and non-invasive method for the simple and reliable collection of potential...Read More ››
The company’s business model is based on generating income from initial sales as well as from repeat sales.Read More ››